Iniciar sesión para ver los precios por organización y contrato.
Seleccione un Tamaño
Cambiar Vistas
Acerca de este artículo
Fórmula empírica (notación de Hill):
C16H21NO3
Número CAS:
Peso molecular:
275.34
UNSPSC Code:
12352200
NACRES:
NA.77
MDL number:
Servicio técnico
¿Necesita ayuda? Nuestro equipo de científicos experimentados está aquí para ayudarle.
Permítanos ayudarleNombre del producto
Rolipram, A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC₅₀ = 800 nM).
Quality Level
description
Merck USA index - 14, 8251
assay
≥98% (HPLC)
form
solid
manufacturer/tradename
Calbiochem®
storage condition
OK to freeze
color
white
solubility
DMSO: soluble
shipped in
ambient
storage temp.
2-8°C
SMILES string
N1CC(CC1=O)c2cc(c(cc2)OC)OC3CCCC3
InChI
1S/C16H21NO3/c1-19-14-7-6-11(12-9-16(18)17-10-12)8-15(14)20-13-4-2-3-5-13/h6-8,12-13H,2-5,9-10H2,1H3,(H,17,18)
InChI key
HJORMJIFDVBMOB-UHFFFAOYSA-N
General description
A cell-permeable, selective inhibitor of cAMP-specific phosphodiesterase (PDE IV; IC50 = 800 nM). A rolipram-insensitive PDE IV subtype is also known to exist. Also inhibits NF-κB and NFAT activation in Jurkat and primary T cells.
Cell permeable, selective competitive inhibitor of cAMP-specific phosphodiesterase IV (IC50 = 800 nM). Rolipram does not inhibit PDE I or PDE II, even at concentrations as high as 100 µM. It is only a weak inhibitor of PDE III (IC50 = 100 µM). A rolipram-insensitive phosphodiesterase IV subtype is also known to exist.
Biochem/physiol Actions
Cell permeable: yes
Primary Target
PDE IV
PDE IV
Product does not compete with ATP.
Reversible: no
Target IC50: 800 nM against cAMP-specific phosphodiesterase (PDE IV)
Preparation Note
Following reconstitution, aliquot and freeze (-20°C). DMSO stock solutions are stable for up to 6 months at -20°C.
Other Notes
Navarro, J., et al. 1998. J. Virol. 72, 4712.
Truong, V.H. and Muller, T. 1994. FEBS Lett.353, 113.
Underwood, D.C., et al. 1994. J. Pharmacol. Exp. Ther. 270, 250.
Moore, J.B., Jr., et al. 1991. Biochem. Pharmacol.42, 679.
Reeves, M.L., et al. 1987. Biochem. J. 241, 535.
Schneider, H.H., et al. 1986. Eur. J. Pharmacol.127, 105.
Truong, V.H. and Muller, T. 1994. FEBS Lett.353, 113.
Underwood, D.C., et al. 1994. J. Pharmacol. Exp. Ther. 270, 250.
Moore, J.B., Jr., et al. 1991. Biochem. Pharmacol.42, 679.
Reeves, M.L., et al. 1987. Biochem. J. 241, 535.
Schneider, H.H., et al. 1986. Eur. J. Pharmacol.127, 105.
Legal Information
CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany
Disclaimer
Toxicity: Irritant (B)
Clase de almacenamiento
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
Certificados de análisis (COA)
Busque Certificados de análisis (COA) introduciendo el número de lote del producto. Los números de lote se encuentran en la etiqueta del producto después de las palabras «Lot» o «Batch»
¿Ya tiene este producto?
Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.
Contenido relacionado
Line M Grønning et al.
FEBS letters, 580(17), 4126-4130 (2006-07-11)
Overexpression of forkhead transcription factor FOXC2 in white adipose tissue (WAT) leads to a lean phenotype resistant to diet-induced obesity. This is due, in part, to enhanced catecholamine-induced cAMP-PKA signaling in FOXC2 transgenic mice. Here we show that rolipram treatment
H Ji
Methods in molecular medicine, 51, 363-377 (2001-01-01)
Angiotensin type-1 receptors (AT(1) receptors) mediate various physiological actions of angiotensin (Ang II) via multiple-signal transduction pathways (1). In addition to the phospholipase C pathway and dihydropyridine-sensitive voltage-dependent calcium channels, AT(1) receptors can couple to inhibition of adenylate cyclase via
Sriram Hemachandran et al.
Frontiers in cellular neuroscience, 18, 1363219-1363219 (2024-05-02)
Cochlear afferent synapses connecting inner hair cells to spiral ganglion neurons are susceptible to excitotoxic trauma on exposure to loud sound, resulting in a noise-induced cochlear synaptopathy (NICS). Here we assessed the ability of cyclic AMP-dependent protein kinase (PKA) signaling